The European registration solidifies global patent protection.
The granting of the European patent now means Paradigm has intellectual property rights in the major pharmaceutical markets of the U.S, Japan and Europe.
During this calendar year, Paradigm will release the results of its two phase II arthritis clinical trials.
Granted patents in Europe, U.S. and Japan along with data from two phase II clinical trials provides a solid foundation for future plans including partnering discussions.
The benefits of drug repurposing
Paradigm is a biotechnology company focused on repurposing PPS, an FDA-approved drug that has a long track record of safely treating inflammation.
Paradigm is repurposing PPS for a number of applications with a focus on treatment of orthopaedic and viral arthritic indications.
Drug repurposing has the benefits of being lower cost, minimises risk and accelerated development timelines.
Paradigm’s strategy is to establish commercial partnerships with multiple leading pharmaceutical companies.